VOLUME 33 , ISSUE 1 (March 2017) - List of articles

Sort by

A field analysis trial comparing the turnaround times of routine and STAT red blood cell immunohematology testing

Katie Sackett/ Andrea Kjell/ Abigail M. Schneider Schneider/ Claudia S. Cohn Cohn

The turnaround time (TAT) for pre-transfusion testing is important for prompt clinical decision-making. TAT includes the time between the arrival of the sample and the initiation of testing, plus the processing time (PT) required to generate and report a result. The TAT in larger blood banks is mostly dependent upon the capability of the analyzer used. In smaller blood banks, where manual work is often performed, the TAT is dependent on availability and experience of staff, testing resources, an(..)

DOI: 10.21307/immunohematology-2019-001

Hemolytic transfusion reaction attributable to anti-Dia

Arthur J. Joyce/ Kelli M Quantock/ Ray Banh/ Yew-Wah Liew

In situations when a patient's antibody detection test is negative, many institutions have moved from an indirect antiglobulin test (IAT) crossmatch to an electronic crossmatch system. Here we report a case of an acute hemolytic transfusion reaction attributable to anti-Dia in a patient with a negative antibody detection test. A 22-year-old female patient with a diagnosis of β thalassemia and sickle cell anemia commenced a routine exchange transfusion of 5 units of red blood cells (RBCs) in the (..)

DOI: 10.21307/immunohematology-2019-002

Modeling alloantibody formation to highincidence red blood cell antigens in immune responders using genotypic data

Patricia A.R. Brunker/ Keerthana Ravindran/ R. Sue Shirey

Alloimmunization to red blood cell antigens is unpredictable and poorly understood. Patients who are negative for highincidence antigens (HIAs) are at risk for developing the corresponding antibodies. Molecular methods can easily predict the lack of an antigen and thus, the risk of an individual to become immunized. We examined the prevalence and risk factors for HIA alloimmunization in patients at risk based on genotyping results. Genotyping using a molecular method (HEA BeadChip™, Immucor, War(..)

DOI: 10.21307/immunohematology-2019-003

Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation

Laura L.W. Cooling/ John Sherbeck/ Jonathon C. Mowers/ Sheri L. Hugan

Ipilimumab, nivolumab, and pembrolizumab represent a new class of immunotherapeutic drugs for treating patients with advanced cancer. Known as checkpoint inhibitors, these drugs act to upregulate the cellular and humoral immune response to tumor antigens by inhibiting T-cell autoregulation. As a consequence, they can be associated with immune-related adverse events (irAEs) due to loss of self-tolerance, including rare cases of immune-related cytopenias. We performed a retrospective clinical char(..)

DOI: 10.21307/immunohematology-2019-004

Use of standard laboratory methods to obviate routine dithiothreitol treatment of blood samples with daratumumab interference

Nicholas J. Lintel/ Debra K. Brown/ Diane T. Schafer/ Farai M. Tsimba-Chitsva/ Scott A. Koepsell/ Sara M. Shunkwiler

Daratumumab is an antibody currently used in the treatment of patients with refractory multiple myeloma. Blood samples from patients being treated with daratumumab may show panreactivity during pre-transfusion testing. To facilitate the provision of blood components for such patients, it is recommended that a baseline phenotype or genotype be established prior to starting treatment with daratumumab. If patient red blood cells (RBCs) require phenotyping after the start of daratumumab treatment, d(..)

DOI: 10.21307/immunohematology-2019-005

Applications of selected cells in immunohematology in a developing country: case studies

Ravi C. Dara Dara/ Aseem Kumar Tiwari/ Dinesh Arora/ Subhasis Mitra/ Geet Aggarwal/ Devi Prasad Acharya/ Gunjan Bhardwaj

When an antibody is detected, its specificity should be determined and its likely clinical significance should be assessed. When one antibody has been identified, it becomes necessary to confirm the presence of additional significant antibodies to ensure that compatible blood is provided to the patient. To perform this confirmation, specific reagent red blood cells (RBCs) are selected; these are called selected cells. Though the most common use of selected cells is for antibody confirmation, the(..)

DOI: 10.21307/immunohematology-2019-006

No Record Found..

Page Actions

Publications

Immunohematology

Journal of Blood Group Serology and Molecular Genetics

FEATURED ARTICLES